Für Poster-/Präsentationen auf nationalen und internationalen Fachkongressen beachten Sie bitte unsere Beispiele auf der Seite Projekte.

Fachzeitschriften (Auswahl):

  • Noe S, Oldenbuettel C, Heldwein S, Wiese C, von Krosigk A, Pascucci R, Ruecker K, Jaeger H, Wolf E. Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe. Horm Metab Res. 2018 Jan 23. doi: 10.1055/s-0043-125073. [Epub ahead of print] PubMed PMID: 29361637.
  • Spinner CD, Kümmerle T, Krznaric I, Degen O, Schwerdtfeger C, Zink A, Wolf E, Klinker HHF, Boesecke C. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study. J Antimicrob Chemother. 2017 Sep 1;72(9):2679-2681.
  • Boretzki J, Wolf E, Wiese C, Noe S, Balogh A, Meurer A, Krznaric I, Zink A, Lersch C, Spinner CD. Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study. Patient Prefer Adherence. 2017, 11:1897-1906.
  • Noe S, Oldenbuettel C, Heldwein S, Jaeger H, Wolf E. Patterns of vitamin D, parathyroid hormone and c-terminal telopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in Central Europe. Infect Dis Rep. 2017 Oct 2;9(3):7265.
  • Wolf E, Noe S. [Long-acting shot against HIV]. MMW Fortschr Med. 2017, 159(Suppl 2):36-38.
  • Wolf E, Noe S. Therapie und Prävention: Depotspritze gegen HIV. MMW Fortschritte der Medizin 2017. S2 / 159: 36-37 (in press) .
  • Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017 Jan;18(1):56-63. doi:10.1111/hiv.12468. PubMed PMID: 27860104.
  • Noe S, Heldwein S, Pascucchi R, Oldenbüttel C, Wiese C, von Krosigk A, Jägel-Guedes E, Jäger H, Mayer W, Spinner CD, Wolf E. Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study. J Int Assoc Provid AIDS Care. 2017 Jan 1:2325957417702487.
  • Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R, Wiese C, Von Krosigk A, Jaegel-Guedes E, Jaeger H, Balogh A, Koegl C, Spinner CD. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 2017;22(2):169-172. doi: 10.3851/IMP3082. Epub 2016 Sep 2.
  • Spinner CD, Kern KE, Zink A, Wolf E, Balogh A, Noe S, Von Werder A, Schwerdtfeger C, Schmid RM, Iakoubov R. Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study. Antivir Ther. 2016;21(7):627-631. doi: 10.3851/IMP3049. PubMed PMID: 27050630.
  • Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016 Mar 13;30(5):753-60. doi: 10.1097/QAD.0000000000000980.
  • Wolf E, Hoffmann C, Schewe K, Klauke S, Baumann R, Karwat M, Schlote F, Mosthaf F, Heiken H, Baumgarten A, Ulmer A, and Jaeger H for the dagnae 50/2010 study group. Symptom and Comorbidity Burden in Chronic Disease: Comparison of HIV-Infection and Diabetes Mellitus in Aging Patients. J AIDS Clin Res 2015; 6: 527. doi:10.4172/2155-6113.1000527.
  • Enders M, Hunjet A, Gleich M, Imdahl R, Mühlbacher A, Schennach H, Chaiwong K, Sakuldamrongpanich T, Turhan A, Sertöz R, Wolf E, Mayer W, Tao C, Wang LL, Semprini S, Sambri V. Performance evaluation of the Elecsys® syphilis assay for the detection of total antibodies to Treponema pallidum. Clin Vaccine Immunol. 2015 Jan;22(1):17-26. doi: 10.1128/CVI.00505-14.
  • Wolf E, Jaeger H. The Concept of the New ERA Study. MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:24-6. German.
  • Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C. HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
  • Dinkel A, Nather C, Jaeger H, Jaegel-Guedes E, Lahmann C, Steinke C, Wolf E, Ronel J. Stigmatization in HIV/AIDS: first German adaptation of the HIV-stigma scale (HSS-D). Psychother Psychosom Med Psychol. 2014 Jan;64(1):20-7. doi: 10.1055/s-0033-1341449. Epub 2013 May 15. German.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, Mayr C, Jaeger H, Pfaff H, Dupke S, Neumann A. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ. 2013 Oct;14(5):799-808. doi: 10.1007/s10198-012-0425-4. Epub 2012 Sep 19.
  • Obermeier M, Pironti A, Berg T, Braun P, Däumer M, Eberle J, Ehret R, Kaiser R, Kleinkauf N, Korn K, Kücherer C, Müller H, Noah C, Stürmer M, Thielen A, Wolf E, Walter H. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology. 2012;55(2):102-7.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study. Eur J Health Econ 2012.
  • Obermeier M, Ehret R, Berg T, Braun P, Korn K, Muller H, Noah C, Stürmer M, Thielen A, Walter H, Wolf E, Kaiser R. Genotypic HIV-coreceptor tropism prediction with geno2pheno [coreceptor]: differences depending on HIV-1-subtype. J Int AIDS Soc 2012; 15(6):18214.Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur J Med Res. 2011 Mar 28;16(3):93-100.
  • Glaubitz J, Sizmann D, Simon CO, Hoffmann KS, Drogan D, Hesse M, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011; 50(2):119-124.
  • Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39(1):3-12.
  • Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, et al. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr 2011; 56(2):109-117.
  • Jaeger H, Wolf E, Simon CO, Babiel R. Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards. J Acquir Immune Defic Syndr 2010; 54(3):334-335.
  • Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res 2010; 15(4):145-151.
  • Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, et al. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naive or pretreated but protease inhibitor-naive HIV-positive patients. Infection 2010; 38(2):108-116.
  • Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, et al. Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54(1):51-58.
  • Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009; 14(7):277-283.
  • Kastenbauer U, Wolf E, Kollan C, Hamouda O, Bogner JR. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease. Eur J Med Res 2009; 14(6):244-249.
  • Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008; 13(8):1091-1095.
  • Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8(5):679-688.
  • Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect 2007; 13(5):510-515.
  • Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, et al. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis. Br J Haematol 2007; 136(4):641-648.
  • Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, van LJ, Stellbrink HJ, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006; 47(9):1872-1880.
  • Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von BF, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20(15):1951-1954.
  • Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr 2006; 131(34-35):1849-1852.
  • Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, et al. Starting or changing therapy – a prospective study exploring antiretroviral decision-making. Infection 2005; 33(4):249-256.
  • Wolf E, Hoffmann C, Procaccianti M, Mosthaf F, Gersbacher E, Ulmer A, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10(2):56-62.
  • Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van LJ, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 2004; 125(4):455-462.
  • Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5(1):15-17.
  • Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17(10):1521-1529.
  • Mauss S, Wolf E, Hans J. Changing incidence of mycobacterial diseases in German patients with HIV infection. AIDS Read 1999; 9(6):386, 391-386, 392.
  • Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3(1):49-55.
  • Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15(16):2119-2127.